FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
    • Publication highlights
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

New research inspirations from Scotland

Professor David Hume came to Cologne to visit the research unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” on October 24th, 2016. Professor Hume is the director of the Roslin Institute at the University of Edinburgh and Professor of Mammalian Functional Genomics there as well.
As an international authority in genome sciences with a particular focus on the macrophage, Professor Hume was able to guide and inspire several research teams of the FOR 2240 that have an interest in exploring the effects of macrophage-colony stimulating factor 1 (CSF1) and its receptor (CSF1R). The role of CSF1 and CSF1R in the eye, and particularly the retina, has not yet been explored in any detail before. Macrophages are specialized cells of the immune system, and their behavior is very specific with respect to such factors as species, gene, organ, and sex. The researchers of the FOR 2240 are especially interested in the role of macrophages in inflammatory diseases of the eye, cancer, and tissue repair.
Professor Hume came to the research unit FOR 2240 at the invitation of Prof. Dr. rer. nat. Thomas Langmann, who is the Vice-Speaker of FOR 2240 and holds the Chair of Experimental Immunology of the Eye in the Department of Ophthalmology at the Medical Faculty of the University of Cologne.
In his clear, understandable lecture, delivered with an engaging native Australian accent, Professor Hume noted numerous interesting findings and ideas of his current work and views, including the following points:
Professor Hume took a critical view of the widespread notion that the inbred mouse model is the best one, noting in particular the shortcomings of its steady-state focus, that is to say, that it does not (yet) adequately address the dynamic workings of macrophage colonies in organs—how the macrophages appear to “reach in” and then “retract” in their interactions with endothelial cells, seemingly “talking” to each other. He stresses that the view over time is important.
Surprisingly, imaging techniques explored by the Roslin team showed that there are even macrophages in muscle tissue, and their role in diseases involving muscle wasting remains to be explored.
The Roslin team has taken a promising new approach in addressing the technical challenges of delivering the small CSF1 protein, namely generating CSF1-fusion proteins, which increase bone density and liver size. Thus, osteoporosis can be added to the list of numerous diseases addressed by Professor Hume in his talk, and here the sex-specificity of the factors regulating macrophage populations is an issue.
One of the further diseases addressed was Crohn’s disease, which the Roslin team proposes to involve rapid turn-over of macrophages.
Professor Hume furthermore proposed that specific gene expression of macrophages is key to understanding various motor neuron diseases.

Related posts

January 7, 2023

Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface


Read more
December 15, 2022

Leonhard Klein-Preis for Prof. Matthaei


Read more
November 22, 2022

4th Shanghai-Cologne Scientific Symposium


Read more

News

  • Rare eye diseases: Eight million euros for research: Funding for four years
  • Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface
  • Experimental Glaucoma Research Group awarded and funded
  • Leonhard Klein-Preis for Prof. Matthaei
  • 4th Shanghai-Cologne Scientific Symposium

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Esther Engel
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
esther.engel@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck